Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,11
KB-1,02
PKN64,9464,96-1,25
Msft428,93428,98-0,25
Nokia3,5313,5935-0,29
IBM169,31169,34-0,90
Mercedes-Benz Group AG66,4866,50,14
PFE28,2628,27-2,13
28.05.2024 21:40:43
Indexy online
AD Index online
select
AD Index online
 

  • 28.05.2024 21:28:31
AIM ImmunoTech Rg (NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,3705 -3,77 -0,01 305 597
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.05.2024
Popis společnosti
Obecné informace
Název společnostiAIM ImmunoTech Inc
TickerAIM
Kmenové akcie:Ordinary Shares
RICAIM
ISINUS00901B1052
Prioritní akcieConv. Pref. Shrs Series B
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.03.2024
Počet zaměstnanců k 31.12.2023 26
Akcie v oběhu k 13.05.2024 51 281 437
MěnaUSD
Kontaktní informace
Ulice2117 SW Highway 484
MěstoOCALA
PSČ34473-7949
ZeměUnited States
Kontatní osobaJenene Thomas
Funkce kontaktní osobyIR Contact Officer
Telefon13 524 487 797
Fax13524804620
Kontatní telefon18 334 758 247

Business Summary: AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Financial Summary: BRIEF: For the three months ended 31 March 2024, AIM ImmunoTech Inc revenues decreased 18% to $40K. Net loss increased 59% to $5.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 68% to $3.7M (expense), Gain (loss) on investments decrease from $203K (income) to $92K (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries
SICCommercial Physical Research



  • Poslední aktualizace: 28.05.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Executive Vice ChairmanThomas Equels7016.10.2019
Chief Financial OfficerRobert Dickey6704.04.202211.06.2009
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, SecretaryPeter Rodino7116.10.201901.10.2016
Chief Scientific and Medical OfficerDavid Strayer7622.02.201601.01.1986